Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| BIOMARKER-RU | UNKNOWN |
Not provided
Not provided
Not provided
The Study Objective is to evaluate the diagnostic efficacy of the liquid biopsy system versus the gold standard mammography (or MRI, or Ultrasound) diagnosis in patients with suspected breast cancer.
Women of the required age group, in case of suspicion of breast cancer, are sent to clarify the diagnosis for mammography or ultrasound of the mammary glands, or MRI. Based on the results of these studies, a biopsy is prescribed to make a final diagnosis. Before a biopsy to diagnose the presence / absence of breast cancer, patients do the blood sampling one time. The blood is processed in the Sponsor's laboratory. The test results are compared with the data obtained from the biopsy. The evaluation of the effectiveness of the method will be determined on the basis of the obtained data on the sensitivity and specificity of the test in relation to the reference method.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Women in age 35 to 65 with suspected breast cancer | Women in age 35 to 65 with suspected breast cancer, previously untreated. Additionally, eligible patients should have appropriate mammography results, either breast ultrasound or breast MRI. |
| |
| Healthy Volunteers | Healthy woman in age 35 to 65. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ARNA Breast | Diagnostic Test | Women of the required age group, in case of suspicion of breast cancer, are sent to clarify the diagnosis for mammography or ultrasound of the mammary glands, or MRI. Based on the results of these studies, a biopsy is prescribed to make a final diagnosis. Before a biopsy to diagnose the presence / absence of breast cancer, patients do the blood sampling one time. The blood is processed in the Sponsor's laboratory. The test results are compared with the data obtained from the biopsy. The evaluation of the effectiveness of the method will be determined on the basis of the obtained data on the sensitivity and specificity of the test in relation to the reference method |
| Measure | Description | Time Frame |
|---|---|---|
| Number of woman with positive ARNA Breast test confirmed by biopsy (Sensitivity) | Primary Measured Values for Efficiency Assessment:
| through study completion, an average of 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Efficiency Evaluation | Estimation of the area under ROC-curve (AUC) | through study completion, an average of 1 year |
| Relationship between test results and the age | Determination of a statistically significant relationship between test results and the age of patients at the time of testing |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Women of the required age group, in case of suspicion of breast cancer, are sent to clarify the diagnosis for mammography or ultrasound of the mammary glands, or MRI but before biopsy.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Andrey Tarabarov, MD | Contact | +79161048621 | at@arna.bio | |
| Egor Melnikov | Contact | +79255022196 | em@arna.bio |
| Name | Affiliation | Role |
|---|---|---|
| Andrey Tarabarov, MD | BIOMARKER-RU | Study Director |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
ARNA technology in general and the ARNA Breast test in particular are performed in a specialized laboratory. The courier service ships whole blood from the Clinic to the Laboratory. Thus, direct contact of the patient with the reagents does not occur, which increases the safety of the system. Plasma will be isolated from the sample in the Laboratory. Plasma is processed with a set of reagents, including inorganic and organic solutions and sets of specially synthesized biological components (oligonucleotides), for real-time polymerase chain reaction (RT-PCR) to determine the content of DNA fragments of selected oncological genes in a woman's blood plasma. The remaining plasma will be kept frozen for retests upon request. Samples will be not transferred to other countries.
|
| through study completion, an average of 1 year |
| Positive predictive value | The ratio of true-positive test results to the total number of positive test results h) the ratio of true negative test results to the total number of negative test results (negative predictive value) i) Positive and negative likelihood ratio | through study completion, an average of 1 year |
| Negative predictive value | The ratio of true negative test results to the total number of negative test results | through study completion, an average of 1 year |
| D017437 |
| Skin and Connective Tissue Diseases |